USANA Health Sciences Reports Third Quarter Results

Rhea-AI Summary

USANA Health Sciences (NYSE: USNA) reported fiscal Q3 2021 results with net sales of $274.4 million, down 8% from the previous year. Diluted EPS was $1.36, a 6% decrease. Active customers dropped to 576,000, down 11%. The Asia Pacific region, contributing 81% of sales, saw net sales of $220.9 million (-9%). The company maintains its fiscal 2021 outlook for consolidated net sales of $1.18 - $1.20 billion and EPS of $5.80 - $6.00. USANA ended the quarter with $249 million in cash.

Positive

• USANA ended Q3 with $249 million in cash and no debt.
• Company expects approximately $130 million of free cash flow in fiscal 2021.
• Reiterates fiscal 2021 outlook for net sales of $1.18 - $1.20 billion and EPS of $5.80 - $6.00.

Negative

• Net sales decreased 8% compared to the prior year.
• Diluted EPS fell 6% compared to the previous year.
• Active customers declined 11%, impacting overall sales.

SALT LAKE CITY--(BUSINESS WIRE)-- USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended October 2, 2021, which were modestly ahead of the preliminary outlook the Company provided on September 16, 2021.

Key Financial & Operating Highlights

• Third quarter net sales were $274.4 million as compared with $298.5 million during the third quarter of the prior year.
• Third quarter diluted EPS were $1.36 versus $1.44 during the third quarter of 2020.
• Reiterates fiscal 2021 net sales and diluted EPS outlook, which was provided on September 16, 2021.
• Company expects to generate approximately $130 million of free cash flow in fiscal 2021.

Q3 2021 Financial Performance

Consolidated Results
Net Sales	$274.4 million	-8% vs. prior-year quarter -11% constant currency vs. prior-year quarter +$9.9 million YOY FX impact, or +3%
Diluted EPS	$1.36	-6% vs. prior-year quarter Diluted shares of 20.2 million, -5%
Active Customers	576,000	-11% vs. prior-year quarter

“As we indicated a month ago, the operating environment remains challenging across several of our key markets due, in great part, to disruptions and lockdowns related to the COVID-19 pandemic,” said Kevin Guest, Chief Executive Officer and Chairman of the Board. “Additionally, the year-over-year comparison was difficult given the significant short-term sales program that we offered in the prior year quarter. Notwithstanding these challenges, we continue to execute our growth strategy, which is centered on generating sustainable customer growth.”

Q3 2021 Regional Results:

Asia Pacific Region
Net Sales	$220.9 million	-9% vs. prior-year quarter Constant currency net sales: -12% 81% of consolidated net sales
Active Customers	443,000	-12% vs. prior-year quarter -14% sequentially
Asia Pacific Sub-Regions
Greater China
Net Sales	$123.2 million	-9% vs. prior-year quarter Constant currency net sales: -15%
Active Customers	246,000	-13% vs. prior-year quarter -19% sequentially
North Asia
Net Sales	$33.1 million	+14% vs. prior-year quarter Constant currency net sales: +12%
Active Customers	63,000	+5% vs. prior-year quarter -5% sequentially
Southeast Asia Pacific
Net Sales	$64.6 million	-15% vs. prior-year quarter Constant currency net sales: -15%
Active Customers	134,000	-15% vs. prior-year quarter -7% sequentially

Americas and Europe Region
Net Sales	$53.5 million	-7% vs. prior-year quarter Constant currency net sales: -9% 19% of consolidated net sales
Active Customers	133,000	-10% vs. prior-year quarter -4% sequentially

Mr. Guest added, “We made progress on several strategic initiatives during the quarter. Enhancing the overall shopping experience for our customers remains a high priority, and to that end, we rolled out additional features and functionality within our China shopping app, as well as a new web-based shopping cart in China. Although our introduction of certain new products has been delayed until 2022, we are actively engaged in bringing new and innovative products to market. Overall, we remain confident that the successful execution of our strategy will deliver long-term, sustainable growth.”

Balance Sheet and Share Repurchase Activity

The Company ended the quarter with $249 million in cash and cash equivalents and no debt after repurchasing 523,000 shares for $50 million. Diluted shares outstanding totaled 20.2 million during the third quarter of 2021. As of October 2, 2021, the Company had approximately $137 million remaining under the share repurchase authorization, following the Company’s increase of the repurchase authorization on September 16, 2021.

Fiscal 2021 Outlook

The Company is reiterating its net sales and earnings per share outlook for fiscal year 2021, which was provided on September 16, 2021.

Fiscal Year 2021 Outlook
	Range
Consolidated Net Sales	$1.18 - $1.20 billion
Diluted EPS	$5.80 - $6.00

The Company maintains a 52/53-week fiscal year. Fiscal 2020 was a 53-week year and included one additional week of sales in the fourth quarter of 2020 compared to Fiscal 2021.

Doug Hekking, Chief Financial Officer, said, “We are reiterating our outlook for fiscal 2021 with third quarter results coming in just ahead of the projections we provided on September 16^th. Our outlook incorporates ongoing investments required to achieve long-term growth objectives that may impact near-term operating margins.”

Management Commentary Document and Conference Call

For more information on the USANA’s operating results, please see the Management Commentary document, which has been posted on the Company’s website (http://ir.usana.com) under the Investor Relations section. USANA’s management team will hold a conference call and webcast to discuss today’s announcement with investors on Wednesday, October 27, 2021 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://ir.usana.com. The call will consist of brief opening remarks by the Company’s management team, followed by a questions and answers session.

Non-GAAP Financial Measures

The Company prepares its financial statements using U.S. generally accepted accounting principles (“GAAP”). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, “Financial Results”) are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates (“FX”) and help facilitate period-to-period comparisons of the Company’s Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results. Free cash flow is a non-GAAP financial measure that we believe provides investors an additional perspective on cash flow from operating activities in excess of amounts required for reinvestment. We believe it provides a measure of our ability to fund various discretionary business initiatives, including acquisitions and share repurchase. Free cash flow is calculated by subtracting net capital expenditures from net cash provided by operating activities.

About USANA

USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, and Italy. More information on USANA can be found at www.usana.com.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: uncertainty related to the magnitude, scope and duration of the impact of the COVID-19 pandemic (“COVID-19”) to our business, operations and financial results; the further spread of, and regulatory measures or voluntary actions that may be put in place to limit the spread of, COVID-19 in the markets where we operate, including restrictions on business operations, shelter at home, or social distancing requirements; the potential for a resurgence of COVID-19 spread in any of our markets in the future; the impact of COVID-19 on the domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; regulatory risk in China in connection with the health products and direct selling business models; regulatory risk in the United States in connection with the direct selling business model; potential negative effects of deteriorating foreign and/or trade relations between the United States and China; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; global economic conditions generally; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model; adverse publicity risks globally; risks associated with our international expansion and operations; and uncertainty relating to the fluctuation in U.S. and other international currencies. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company’s expectations, except as required by law.

USANA Health Sciences, Inc.
Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)
		Quarter Ended								Nine Months Ended
		2-Oct-21				26-Sep-20				2-Oct-21			26-Sep-20
Net sales		$	274,352			$	298,513			$	919,165		$	824,123
Cost of sales			50,715				56,358				165,380			150,091
Gross profit			223,637				242,155				753,785			674,032
Operating expenses:
Associate incentives			116,222				131,144				404,580			358,065
Selling, general and administrative			66,645				65,656				210,518			192,014
Earnings from operations			40,770				45,355				138,687			123,953
Other income (expense), net			(420	)			(1,080	)			309			(536	)
Earnings before income taxes			40,350				44,275				138,996			123,417
Income taxes			13,020				13,769				42,811			38,382
NET EARNINGS		$	27,330			$	30,506			$	96,185		$	85,035
Earnings per share - diluted		$	1.36			$	1.44			$	4.68		$	4.00
Weighted average shares outstanding - diluted			20,156				21,170				20,566			21,283

USANA Health Sciences, Inc.
Consolidated Balance Sheets
(In thousands)
(Unaudited)
		As of			As of
		2-Oct-21			2-Jan-21
ASSETS
Current Assets
Cash and cash equivalents		$	248,695		$	311,917
Inventories			96,316			90,224
Prepaid expenses and other current assets			23,414			23,145
Total current assets			368,425			425,286
Property and equipment, net			100,957			100,445
Goodwill			17,510			17,367
Intangible assets, net			30,312			30,796
Deferred tax assets			5,465			4,640
Other assets			56,277			62,353
Total assets		$	578,946		$	640,887
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable		$	13,706		$	18,195
Other current liabilities			144,258			149,878
Total current liabilities			157,964			168,073
Deferred tax liabilities			7,840			12,009
Other long-term liabilities			14,063			19,155
Stockholders' equity			399,079			441,650
Total liabilities and stockholders' equity		$	578,946		$	640,887

USANA Health Sciences, Inc.
Sales by Region
(unaudited)
(in thousands)
		Quarter Ended
		October 2, 2021						September 26, 2020						Change from prior year							Currency impact on sales			% change excluding currency impact
Asia Pacific
Greater China		$	123,235		44.9	%		$	136,013		45.5	%		$	(12,778	)		(9.4	%)		$	7,457		(14.9	%)
Southeast Asia Pacific			64,570		23.5	%			76,313		25.6	%			(11,743	)		(15.4	%)			85		(15.5	%)
North Asia			33,068		12.1	%			28,969		9.7	%			4,099			14.1	%			770		11.5	%
Asia Pacific Total			220,873		80.5	%			241,295		80.8	%			(20,422	)		(8.5	%)			8,312		(11.9	%)
Americas and Europe			53,479		19.5	%			57,218		19.2	%			(3,739	)		(6.5	%)			1,570		(9.3	%)
		$	274,352		100.0	%		$	298,513		100.0	%		$	(24,161	)		(8.1	%)		$	9,882		(11.4	%)

Active Associates by Region(1)
(unaudited)
		As of
		October 2, 2021				September 26, 2020
Asia Pacific
Greater China		81,000		29.8%		91,000		29.1%
Southeast Asia Pacific		90,000		33.1%		113,000		36.1%
North Asia		39,000		14.3%		39,000		12.4%
Asia Pacific Total		210,000		77.2%		243,000		77.6%
Americas and Europe		62,000		22.8%		70,000		22.4%
		272,000		100.0%		313,000		100.0%
Active Preferred Customers by Region (2)
(unaudited)
		As of
		October 2, 2021				September 26, 2020
Asia Pacific
Greater China		165,000		54.3%		193,000		57.3%
Southeast Asia Pacific		44,000		14.4%		45,000		13.4%
North Asia		24,000		7.9%		21,000		6.2%
Asia Pacific Total		233,000		76.6%		259,000		76.9%
Americas and Europe		71,000		23.4%		78,000		23.1%
		304,000		100.0%		337,000		100.0%

(1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale.

(2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211026006199/en/

Investor contact:

Patrique Richards

Investor Relations

(801) 954-7961

investor.relations@usanainc.com



Media contact:

Dan Macuga

Public Relations

(801) 954-7280

Source: USANA Health Sciences, Inc.

FAQ

What are USANA's Q3 2021 net sales?

USANA reported net sales of $274.4 million for Q3 2021.

How did USANA's diluted EPS perform in Q3 2021?

Diluted EPS for Q3 2021 was $1.36, a 6% decrease from the previous year.

What is USANA's outlook for fiscal year 2021?

USANA maintains its outlook for fiscal 2021 with net sales expected between $1.18 - $1.20 billion and EPS of $5.80 - $6.00.

What is the current status of USANA's active customers?

As of Q3 2021, USANA has 576,000 active customers, a decrease of 11% year-over-year.

What cash reserves does USANA have at the end of Q3 2021?

USANA ended Q3 2021 with $249 million in cash and cash equivalents.